connections

Novartis Oncology Facts

Global Oncology Headquarters in East Hanover, NJ

More than 10,000 associates worldwide

22 marketed and mature products in oncology, hematology and

rare diseases

Over 25 new molecules in development

8 research & development sites around the globe

Growing our potential for patients Novartis Oncology is a global leader in providing a broad range of innovative therapies to help improve the lives of cancer patients. Recently, we have completed the acquisition of the GSK oncology portfolio, a landmark achievement in our more than decade-long commitment to address unmet medical needs in oncology, hematology and rare diseases. This milestone creates tremendous potential for the future and our collaboration with the oncology community. It is our hope that the integration of the GSK oncology portfolio will enable our organization to serve healthcare professionals more broadly, to bring new solutions to more patients and to explore the potential of novel combinations that target multiple disease pathways.

More than ever, Novartis Oncology has a truly global reach. We have the advantage of more than 10,000 extraordinarily talented and globally diverse associates in 85 countries who, through shared goals and different perspectives, are dedicated to helping deliver more therapies to more patients in their fight against cancer. We now offer one of the largest portfolios of medicines in oncology, hematology and rare diseases. And, with more than 25 new molecules in development targeting key molecular pathways in cancer biology, we believe the opportunity to improve outcomes has never been greater.

Together, we are turning scientific possibility into clinical reality.

www.NovartisOncology.com

Novartis Oncology is a business unit in the Pharmaceuticals Division of Novartis AG. For more information about Novartis AG visit www.novartis.com

Bruno Strigini, President, Novartis Oncology

Acromegaly Acute lymphocytic leukemia Anemia

Bone complications due to bone metastases from solid tumors

Breast cancer Carcinoid tumors

Cervical cancerChemotherapy-induced nausea and vomiting

Chronic eosinophilic leukemia (CEL)

Chronic lymphocytic leukemia (CLL) Chronic myeloid leukemia Cushing’s disease

Dermatofibrosarcoma protuberans (DFSP)

Gastrointestinal stromal tumors Hypereosinophilia

Iron overload Lung cancer Lymphoma

Melanoma Multiple myelomaMyelodysplastic/

myeloproliferative disease

Myelofibrosis Neuroendocrine tumors Ovarian cancer

Renal cell carcinomaSubependymal giant cell

astrocytoma (SEGA) tumorsSoft tissue sarcoma

T-cell acute lymphoblastic leukemia Thrombocytopenia

About Novartis OncologyAt Novartis Oncology, our mission is to help improve the lives of cancer patients. We are passionate about the discovery and development of innovative medicines that transform the way people live with cancer and rare diseases. We seek to provide a wide range of innovative therapies to help meet unmet medical needs, as well as practical solutions to advance the care of patients. But we don’t do this alone.

Making connections in science and building relationships with people in the oncology community fuels our ability to deliver innovative medicines for patients. More than a decade ago, Novartis AG was the first company to form a dedicated global business unit to develop and launch innovative oncology medicines. Continued commitment to this early vision has grown Novartis Oncology into a global leader in oncology, hematology and rare diseases with an unmatched portfolio of products and one of the strongest and most productive pipelines in the industry.

Our success in oncology drug development has taught us the value of our connections within the oncology community and their importance to innovation. Together, we explore novel compounds in clinical development as we seek to advance or create new standards of care.

Our strategy is comprised of three elements:

• Precision Oncology evolves our understanding of how cancer develops on a genomic level, with potential for better patient outcomes

• Open Partnerships within the oncology community enable us to realize the power of collaboration, leading to the development of breakthrough therapies that impact patients’ lives

• Patient-Inspired Solutions drive us to connect with patient groups and others in the oncology community to help us understand and reflect patient needs

Novartis Oncology offers an unmatched portfolio of 22 oncology, hematology and rare disease medicines to treat more than 25 conditions worldwide. New therapies acquired from the GSK oncology portfolio in melanoma, renal cell carcinoma and hematology complement Novartis Oncology’s existing group of practice-changing medicines to create one of the largest portfolios of drugs in oncology and hematology targeting important biological disease pathways. The breadth of this new portfolio enables Novartis Oncology to provide customers with more complete offerings to treat several forms of cancer, reaching more patients with greater potential impact.

Novartis Oncology has therapies that treat specific forms of the following diseases:

Novartis Oncology is helping improve the lives of cancer patients with precision oncology treatments

Acquired from GSK

Therapies to treat all of the above disease areas may not be available in all countries. For more information on our therapies, please visit NovartisOncology.com/Products.jsp

Leveraging Unique, Dedicated Global CapabilitiesOur worldwide commercial and development capabilities encompass more than 10,000 associates working in 85 countries, eight research and development facilities on three continents and broad operational facilities across the globe. Further enhancing our organization’s research and development capabilities, Novartis Oncology collaborates with research cooperatives worldwide. From Canada to Australia, our wide range of global partnerships allows us to share insights, build knowledge and realize the full potential of working together.

The acquisition of the GSK oncology portfolio strengthens our industry-leading pipeline in precision cancer treatment, brings exciting potential to the development of combination regimens and further expands one of the largest clinical development programs in oncology.

The addition of the GSK oncology portfolio builds on our strength in targeted therapies, further positioning Novartis as one of the best potential collaborators in the industry. By leveraging innovative scientific partnerships and internal capabilities,

Novartis is developing a growing presence in the revolutionary new area of cancer immunotherapies, including next-generation checkpoint inhibitors. Additionally, through our Cell & Gene Therapies Unit, Novartis is building an expanding portfolio of chimeric antigen receptor therapies (CARTs).

Over 25 new molecules in development

Targeting 19 cancer pathways

More than 340 active, global trials

Enrolling more than 25,000 patients

Leading Through Precision OncologyAt Novartis, our approach is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. These efforts begin in the Novartis Institutes for BioMedical Research (NIBR) where Oncology research focuses on unmet medical needs and disease pathways to:

• Identify pathways most commonly associated with cancer

• Screen compounds to identify ones with greatest potential to impact pathways

• Identify biomarkers which can be used to determine which patients are most likely to benefit from therapy

Our colleagues in NIBR manage compounds through exploratory human trials up to the determination of Proof of Concept, at which point, they transition to Oncology Global Development & Global Medical Affairs (OGD&GMA) for full clinical development.

California, US (NIBR)

Massachusetts, US (NIBR & OGD&GMA)

New Jersey, US (NIBR & OGD&GMA)

Paris, France (OGD&GMA)

Basel, Switzerland (NIBR & OGD&GMA)

Tokyo, Japan (OGD&GMA)

Hyderabad, India (OGD&GMA)

Shanghai, China (NIBR)

Impacting Patients Around the GlobeNovartis Oncology shares a common goal with the global oncology community – to improve and extend the lives of people with cancer. Through open partnerships with the community we gain and build knowledge, driving clinical development based on scientific and patient insights.

• Partnering with healthcare professionals enables us to conduct high-quality clinical trials with competitive timelines and aids in the discovery of new uses of our medicines to benefit patients.

• Engagement with advocacy groups helps us better understand patient needs and barriers to treatment success.

• Collaboration with health authorities helps us to speed delivery of new treatments for patients.

Since launching the Glivec International Patient Assistance Program (GIPAP) in 2002, Novartis Oncology’s track record of innovative access programs and disease alliances is unmatched in the industry. With new products in the portfolio, we will develop new connections and leverage existing relationships to improve outcomes and the availability of medicines.

We recognize the challenges of access are varied across the globe. Successful access solutions depend on collaboration among industry, governments, NGOs, healthcare professionals, payers and patient advocates to address the specific requirements and barriers in each country. In low-to-middle income countries, Novartis Oncology Access (NOA) facilitates innovative public-private partnerships to create sustainable access for patients in need. Throughout our history, this approach has expanded access to oncology medicines for more than 80,000 patients in low-to-middle income countries across Central and South America, Africa, Middle East, Eastern Europe, Asia and the Pacific Islands.

About NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). As of December 31, 2014, Novartis Group companies employed approximately 133,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

www.novartisoncology.com

Novartis Pharma AGCH-4002 Basel Switzerland ©Novartis 2015 01/15 G-ONC-1107418

Connect with us today.